About AUPH

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AUPH is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 219.3 M 2.1934E+08 234 234 0.03% 0.000320257 149 K 149024
UBIO Proshares UltraPro Nasdaq Biotechnology 29.3 M 2.93379E+07 227 227 0.02% 0.000205159 19 K 19010
IBB iShares Nasdaq Biotechnology Index Fund 7.4 B 7.39335E+09 221 221 0.08% 0.0008 5.7 M 5679730